Vittorio Gebbia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1844088/publications.pdf

Version: 2024-02-01

79 papers	10,617 citations	147726 31 h-index	71651 76 g-index
79 all docs	79 docs citations	79 times ranked	11150 citing authors

#	Article	IF	Citations
1	Cancer: New Needs, New Models. Is It Time for a Community Oncologist? Another Brick in the Wall. Cancers, 2021, 13, 1919.	1.7	6
2	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials. BMC Cancer, 2021, 21, 549.	1.1	10
3	Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis. Future Science OA, 2021, 7, FSO750.	0.9	5
4	Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis. Ecancermedicalscience, 2020, 14, 1113.	0.6	5
5	Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials. Lung Cancer, 2019, 133, 62-68.	0.9	5
6	A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients. Lung Cancer, 2017, 108, 15-21.	0.9	10
7	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 57528-57536.	0.8	7
8	Oral Chemotherapy and Patient Perspective in Solid Tumors: A National Survey by the Italian Association of Medical Oncology. Tumori, 2016, 102, 108-113.	0.6	4
9	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology, 2015, 33, 910-915.	0.8	361
10	Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study. Lung Cancer, 2013, 81, 77-83.	0.9	51
11	Treatment Monitoring Program for Implementation of Adherence to Second-Line Erlotinib for Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 390-398.	1.1	48
12	Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM). Tumori, 2013, 99, 35-38.	0.6	3
13	Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opinion on Drug Safety, 2012, 11, S49-S59.	1.0	38
14	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1830-1844.	0.5	23
15	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, The, 2012, 13, 239-246.	5.1	4,943
16	First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology, 2012, 30, 3002-3011.	0.8	229
17	Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials. Lung Cancer, 2012, 76, 457-464.	0.9	32
18	Does pain intensity predict a poor opioid response in cancer patients?. European Journal of Cancer, 2011, 47, 713-717.	1.3	18

#	Article	IF	Citations
19	Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Lifeâ€"Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Nonâ€"Small-Cell Lung Cancer (ERACLE). Clinical Lung Cancer, 2011, 12, 402-406.	1.1	11
20	Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial. Journal of Clinical Oncology, 2011, 29, 3628-3635.	0.8	182
21	Morphine Versus Oxycodone in Pancreatic Cancer Pain. Clinical Journal of Pain, 2010, 26, 794-797.	0.8	46
22	Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 461-464.	0.6	40
23	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. Journal of Clinical Oncology, 2010, 28, 1645-1651.	0.8	279
24	Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer, 2010, 67, 86-92.	0.9	23
25	First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer, 2010, 69, 218-224.	0.9	17
26	Anticancer oral therapy: Emerging related issues. Cancer Treatment Reviews, 2010, 36, 595-605.	3.4	139
27	Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trials. European Journal of Cancer, 2010, 46, 735-743.	1.3	71
28	Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Nonâ€"Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 1836-1843.	0.8	166
29	Evolution of Therapy Decision-Making Process for Advanced Non-Small Cell Lung Cancer. Oncology, 2009, 77, 97-102.	0.9	1
30	Adjuvant Therapy in Colon Cancer. Oncology, 2009, 77, 50-56.	0.9	13
31	Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. Lung Cancer, 2009, 63, 251-258.	0.9	31
32	Tools for Identifying Cancer Pain of Predominantly Neuropathic Origin and Opioid Responsiveness in Cancer Patients. Journal of Pain, 2009, 10, 594-600.	0.7	65
33	Sustainedâ€release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European Journal of Pain, 2008, 12, 1040-1046.	1.4	117
34	Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: A prospective randomized phase III trial of the G.O.I.M. (Gruppo) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137 Td	0.9	35
35	Correlation between basal bilirubin levels and survival in advanced colorectal carcinoma treated with CPT-11-based chemotherapy: A study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). European Journal of Cancer, Supplement, 2008, 6, 94-99.	2.2	0
36	Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy, 2008, 9, 1321-1337.	0.9	4

#	Article	IF	Citations
37	Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncology, The, 2007, 8, 500-512.	5.1	89
38	Oral Vinorelbine in the Treatment of Non-Small Cell Lung Cancer. Drugs, 2007, 67, 1403-1410.	4.9	33
39	Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicenter Experience. Clinical Colorectal Cancer, 2006, 5, 422-428.	1.0	30
40	Treatment of Metastatic Breast Cancer With Vinorelbine and Docetaxel. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 276-280.	0.6	6
41	Oral Vinorelbine May Not Induce Acute Pain at the Tumor Site. Journal of Pain and Symptom Management, 2006, 32, 197-199.	0.6	7
42	Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer, 2006, 6, 202.	1.1	21
43	Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Nonâ€"Small-Cell Lung Cancer Receiving Chemotherapy: A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderly Study. Journal of Clinical Oncology, 2005, 23, 6865-6872.	0.8	452
44	Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dellâ€™Italia Meridionale. Journal of Clinical Oncology, 2005, 23, 4866-4875.	0.8	693
45	Oral versus intravenous vinorelbine: clinical safety profile. Expert Opinion on Drug Safety, 2005, 4, 915-928.	1.0	62
46	Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncology, The, 2005, 6, 669-677.	5.1	197
47	Phase Iâ€"II Parallel Study of Docetaxel on a Bimonthly Schedule in Refractory Metastatic Breast Carcinoma. Breast Cancer Research and Treatment, 2003, 77, 99-108.	1.1	4
48	Supportive care in patients with advanced non-small-cell lung cancer. British Journal of Cancer, 2003, 89, 1013-1021.	2.9	27
49	Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIBâ€"IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer, 2003, 39, 179-189.	0.9	46
50	Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial. Journal of the National Cancer Institute, 2003, 95, 362-372.	3.0	768
51	Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Nonâ€"Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 2003, 21, 3025-3034.	0.8	232
52	Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIBâ€"IV non-small cell lung carcinoma: a prospective randomized study. Lung Cancer, 2002, 37, 179-187.	0.9	25
53	Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma. Cancer, 2002, 94, 902-910.	2.0	347
54	Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II Study. Journal of Clinical Oncology, 2001, 19, 4089-4091.	0.8	126

#	Article	IF	Citations
55	5-Fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma. Cancer, 1999, 85, 535-545.	2.0	16
56	Epirubicin, Folinic Acid, Fluorouracil, and Etoposide in the Treatment of Advanced Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1999, 22, 262-266.	0.6	5
57	Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. , 1997, 79, 1394-1400.		16
58	Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule: Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). , 1996, 78, 1300-1307.		44
59	Treatment of Stage III-IV Non-Small-Cell Lung Carcinoma with Vinorelbine in Combination with Ifosfamide plus MESNA: A Study by the Southern Italy Oncology Group (GOIM). American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 278-280.	0.6	11
60	Phase I Study of Chemotherapy with Carboplatin, Epirubicin, and Escalating Dose of VP-16 with G-CSF Support in Extensive Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 589-591.	0.6	3
61	Vinorelbine Plus Cisplatin in Recurrent or Previously Untreated Unresectable Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 1995, 18, 293-296.	0.6	15
62	Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer, 1995, 76, 535-536.	2.0	15
63	Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer, 1995, 76, 1821-1828.	2.0	25
64	Phase II Study of the Etoposide, Leucovorin and Fluorouracil Combination for Patients with Advanced Gastric Cancer Unsuitable for Aggressive Chemotherapy. Oncology, 1995, 52, 41-44.	0.9	24
65	Mitomycin Â«CÂ» and Vinorelbine as Second Line Chemotherapy for Metastatic Breast Carcinoma. Tumori, 1994, 80, 33-36.	0.6	13
66	Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial. Cancer, 1994, 74, 1945-1952.	2.0	71
67	A Phase Iâ€"II Study of Cyclophosphamide, Epidoxorubicin, Levofolinic Acid/5-Fluorouracil and Recombinant Human Granulocyte Colony Stimulating Factor in Metastatic Breast Carcinoma. Acta OncolÃ³gica, 1994, 33, 925-929.	0.8	2
68	Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Orl, 1994, 56, 279-282.	0.6	7
69	Weekly Levofolinic Acid and 5-Fluorouracil Plus Hydroxyurea in Metastatic Gastrointestinal Adenocarcinomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 485-489.	0.6	5
70	Carboplatin, Epirubicin, and VP-16 Chemotherapy in the Treatment of Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 160-162.	0.6	7
71	A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer, 1993, 29, 1358-1359.	1.3	38
72	A Phase II Study of Levofolinic Acid and 5-Fluorouracil Plus Cisplatin in Patients with Advanced Head and Neck Squamous Cell Carcinoma. Oncology, 1993, 50, 490-494.	0.9	9

#	Article	IF	Citations
73	Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anti-Cancer Drugs, 1993, 4, 443-446.	0.7	49
74	Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy. Anti-Cancer Drugs, 1992, 3, 347-350.	0.7	6
75	Cisplatinum in Combination with 5-Fluorouracil and Citrovorum Factor in the Treatment of Advanced Colorectal Carcinoma. Cancer Investigation, 1992, 10, 497-504.	0.6	5
76	High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck. Journal of Cancer Research and Clinical Oncology, 1992, 118, 458-462.	1.2	9
77	Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with gluthatione protection in patients with advanced head and neck cancer. Medical Oncology and Tumor Pharmacotherapy, 1992, 9, 165-168.	1.0	4
78	Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer. Journal of Cancer Research and Clinical Oncology, 1991, 117, 266-268.	1.2	4
79	Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients. Journal of Cancer Research and Clinical Oncology, 1989, 115, 579-582.	1.2	10